Syngene down in the red

Syngene’s performance was not too inspiring with consolidated net profit for Q4FY25 slipping 3% (YoY) to Rs.183 crore and this was on a 11% rise in revenue from operations at Rs.1019 crore. Ebitda margin for the quarter fell to 35 per cent against 35.7 per cent YoY.  

More than the performance the market was worried with the muted guidance.

Post Q4 results, Managing Director and CEO at Syngene International, Peter Bains, said revenue growth is expected to be in the early teens that he said reflected a broad-based growth across research, development and manufacturing services. But adjusted for inventory balancing in large molecule commercial manufacturing at client level, Bains expected revenue growth to be only in mid-single digits. 

CFO Deepak Jain said Ebitda margin may moderate to mid-twenties and YoY PAT may see some decline.

Following this, the stock is down in the red, top loser on the BSE and currently down 12.5% at Rs.656 levels. Its 52-week low is at Rs.608.